

## Russian experience of Laennec administration in patients after COVID-19

座長：長瀬 眞彦 吉祥寺クリニック・院長

The Laennec preparation produced from a standardized hydrolyzate of placenta has been used for many years as an effective and safe hepatoprotector. However, the molecular composition of Laennec, which includes numerous peptide fragments of placental proteins, suggests much wider a range of clinical applications of this drug. In particular, studies of the peptide composition of Laennec, conducted using hybrid proteomic technologies and modern procedures of data analysis, indicated a high regenerative potential of the drug. The data available from experimental and clinical studies show that the regenerative effect of the drug is very broad and by no means limited to the regeneration of the liver parenchyma. The regenerative effect of Laennec has been shown in cut wound/burn models and in patients treated after severe post-traumatic and burn scars of the skin. The use of Laennec as part of complex therapy led to an improvement in the morphological structure of the skin in the area of damage and to a noticeable aesthetic effect (disappearance of the scarring and complete healing of the skin). Experimental and clinical studies have demonstrated the effectiveness of Laennec in the treatment of porphyrin skin aging. On the model of liver hemosiderosis (iron sulfate overload) Laennec contributed to the elimination of hemosiderosis and restoration of the normal liver parenchyma. Clinical studies have confirmed the effectiveness of Laennec in the treatment of hemosiderosis, hyperferritinemia and fatty liver disease. The regenerative effect of Laennec has been shown in a model of adrenaline myocardial damage in rats; a promising application of Laennec is to treat endotheliopathy. In a clinical study of women with underdeveloped endometrium preparing for IVF/ICSI procedures, Laennec contributed to the restoration of sufficient endometrial height without hyperproliferation and, subsequently, to successful pregnancy. The regenerative effects of Laennec in patients with severe course of COVID-19 were manifested as hepatoprotection (decrease in excessive levels of AST and ALT), a decrease in hyperferritinemia, and a decrease in the area of lung damage according to CT. An indirect confirmation of the general regenerative properties of Laennec is a significant (1.5-3 times) increase in the lifespan of *C.elegans* model animals under conditions of thermal or toxic stress. Studies of the composition of Laennec made it possible to identify peptides that determine the regenerative properties of the drug.

### 指定演題 3

Doctor of Medical Sciences, Professor, Academic of the Russian Academy of Sciences.

**Alexander Chuchalin** (アレクサンドル・チュチャーリン)

---

#### Education :

1963 Pirogov Russian National Research Medical University, Moscow, Russia

1963-1965 Clinical residency

1965-1967 Post-graduate courses

1967 Candidate thesis

1974 Doctoral thesis, Chairman of the department of hospital therapy at the Pirogov Russian National Research Medical University


1982 Corresponding member of the USSR Academy of Medical Sciences (Russian Academy of Sciences)

1987-1990 Vice-president of the USSR Academy of Medical Sciences

1990 Chuchalin founded Research Institute of Pulmonology

2003 First Russian winner of the Golden Hippocrates international prize.

2006 The Order "For Merit to the Fatherland"



### 指定演題 4

Doctor of Medical Sciences, Professor, Scientific Supervisor of the Institute of Pharmacoinformatics (FIC IU of Russian Academy of Sciences)

**Olga Gromova** (オルガ・グロモヴァ)

---

#### Education :

1984 Ivanovo State Medical Academy, Ivanovo, Russia

1984-1987 Assistant of the Department of Pharmacology, IvGMA, Ivanovo

1988-1992 PhD in Clinical Pharmacology, St. Petersburg Medical University, St. Petersburg

1992 PhD thesis in Clinical Pharmacology

1992-2003 Associate Professor of the Department of Pharmacology

2000 Doctoral thesis in Clinical Pharmacology

2003 Professor of Clinical Pharmacology

2017 Scientific Supervisor of the Institute of Pharmacoinformatics of the Federal Research Center for Informatics and Management of the Russian Academy of Sciences.

